Generic Name and Formulations:
Pegfilgrastim (polyethylene glycol/filgrastim conjugate) 6mg/0.6mL soln; SC inj; preservative-free.

Company:
Amgen, Inc.
Indications for NEULASTA:
To decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anticancer drugs associated with clinically significant incidence of febrile neutropenia.

Adult:
Do not give between 14 days before and 24 hours after chemotherapy. Adolescents <45 kg: not recommended. ≥45 kg: 6mg SC once per chemotherapy cycle.

Children:
Not recommended.

Contraindications:
Do not use for peripheral blood progenitor cell (PBPC) mobilization. Hypersensitivity to E. coli-derived products.

Warnings/Precautions:
Monitor CBC and platelets before and during therapy. Monitor for splenomegaly/splenic rupture and for adult respiratory distress syndrome (ARDS); suspend until ARDS resolves if fever or lung infiltrates occur. Sickle cell disease (may cause sickle cell crisis). Myeloid malignancies. Myelodysplasia. Pregnancy (Cat.C). Nursing mothers.

Interactions:
Caution with drugs that cause delayed myelosuppression (eg, nitrosoureas, mitomycin C), or increase release of neutrophils (eg, lithium), antimetabolites (eg, 5-FU), and radiation therapy.

Pharmacological Class:
Granulocyte colony stimulating factor.

Adverse Reactions:
Bone pain, anaphylaxis, ARDS; splenic rupture (rare).

How Supplied:
Prefilled syringe—1